Works matching IS 17562856 AND DT 2017 AND VI 10 AND IP 1
Results: 7
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 41, doi. 10.1177/1756285616676065
- By:
- Publication type:
- Article
Reliability and validity of the Attributional Style Questionnaire -- Survey in people with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 33, doi. 10.1177/1756285616673515
- By:
- Publication type:
- Article
Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 67, doi. 10.1177/1756285616671887
- By:
- Publication type:
- Article
Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 18, doi. 10.1177/1756285616671882
- By:
- Publication type:
- Article
Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 3, doi. 10.1177/1756285616670060
- By:
- Publication type:
- Article
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 51, doi. 10.1177/1756285616666741
- By:
- Publication type:
- Article
Plasma exchange as a cost-effective option for treating Guillain-Barré syndrome.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 76, doi. 10.1177/1756285616659978
- By:
- Publication type:
- Article